CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
β-1,3/1,6-D-glucan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02402296
NCT02402296Phase 4Completed
CompareCT.gov

Efficacy of β-glucan in Treatment of Localized Aggressive Periodontitis: A Short Term Double-blinded, Placebo-controlled, Randomized Clinical Trial

Al-Azhar University·interventional·Posted Mar 30, 2015·Updated Jun 9, 2015

In Brief

A Phase 4 clinical trial evaluating β-1,3/1,6-D-glucan and Placebo for Localized Aggressive Periodontitis. Completed, enrolled 30 participants.

Detailed Summary

combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocalized Aggressive Periodontitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2015
Enrollment StartJan 1, 2013
Primary CompletionJun 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.3 years ago

Interventions

β-1,3/1,6-D-glucandrug

15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.

Placeboother

15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.